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MaBACKGROUND Familial hypercholesterolemia is typically caused by LDL receptor (LDLR) mutations that result in
elevated levels of LDL cholesterol (LDL-C). In homozygous FH, the prevalence of aortic valve calciﬁcation (AoVC) reaches
100% and is often symptomatic.
OBJECTIVES The objective of this study was to investigate the prevalence, extent, and risk-modiﬁers of AoVC in
heterozygous FH (he-FH) that are presently unknown.
METHODS Asymptomatic patients with he-FH and 131 non-familial hypercholesterolemia controls underwent
CT computed tomography calcium scoring. AoVC was deﬁned as the presence of calcium at the aortic valve leaﬂets.
The extent of AoVC was expressed in Agatston units, as the AoVC-score. We compared the prevalence and extent
of AoVC between cases and controls. In addition, we investigated risk modiﬁers of AoVC, including the presence
of LDLR mutations without residual function (LDLR-negative mutations), maximum untreated LDL-cholesterol
(maxLDL), LDL-C, blood pressure, and coronary artery calciﬁcation (CAC).
RESULTS We included 145 asymptomatic patients with he-FH (93 men; mean age 52  8 years) and 131 non-familial
hypercholesterolemia controls. The prevalence (%) and AoVC-score (median, IQR) were higher in he-FH patients than in
controls: 41%, 51 (9–117); and 21%, 21 (3–49) (p < 0.001 and p ¼ 0.007). Age, untreated maxLDL, CAC, and diastolic
blood pressure were independently associated with AoVC. LDLR-negative mutational he-FH was the strongest predictor
of the AoVC-score (OR: 4.81; 95% CI: 2.22 to 10.40; p ¼ <0.001).
CONCLUSIONS Compared to controls, he-FH is associated with a high prevalence and a large extent of subclinical
AoVC, especially in patients with LDLR-negative mutations, highlighting the critical role of LDL-C metabolism in AoVC
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ABBR EV I A T I ON S
AND ACRONYMS
AoVC = aortic valve
calciﬁcation
CAC = coronary artery
calciﬁcation
CAD = coronary artery disease
CT = computed tomography
FH = familial
hypercholesterolemia
he-FH = heterozygous familial
hypercholesterolemia
LDL-C = low-density
lipoprotein cholesterol
LDLR = low-density lipoprotein
receptor
maxLDL = maximum low-
density lipoprotein cholesterol
NACP = nonanginal chest pain
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2688A ortic valve calciﬁcation (AoVC) hasan estimated prevalence of >50% inthe elderly (i.e., those aged >75
years) and is associated with an elevated
risk of coronary (72%) and cardiovascular
(50%) events (1,2). In addition, the degree of
AoVC correlates with severity of stenosis,
disease progression, and the development
of coronary and cardiovascular events (3–5).
In the general population, AoVC is
associated with age, male sex, smoking, hy-
pertension, diabetes, obesity, and hypercho-
lesterolemia (6,7). Patients with familial
hypercholesterolemia (FH) have extremely
high levels of low-density lipoprotein
cholesterol (LDL-C) and may be at high risk
for developing AoVC. FH is an autosomal
inherited disorder caused by mutations in
the LDL receptor (LDLR) gene, the apolipo-protein B (APOB) gene, or the proprotein convertase
subtilisin/kexin type 9 (PCSK9) gene (8). LDLR muta-
tions can be classiﬁed as mutations with residual
LDLR function (LDLR-defective mutations) or without
LDLR function (LDLR-negative mutations) (9).SEE PAGE 2696In patients who are homozygous for FH, the
prevalence of AoVC reaches 100%, and surgical
intervention of functional valvular disease is often
needed (10,11). Compared with homozygous FH,
heterozygous familial hypercholesterolemia (he-FH)
is associated with less aortic valve dysfunction on
echocardiography (12–15). However, the prevalence of
AoVC in he-FH is unknown.
The purpose of the present single-center study was
to determine the prevalence and extent of AoVC in
asymptomatic statin-treated patients, heterozygous
for FH. In addition, we evaluated which variables
were associated with the presence and extent of
AoVC. In the molecular context of the patients, AoVC
was compared between he-FH patients with and
without LDLR-negative mutations.
METHODS
STUDY POPULATION. Between February 2008 and
June 2011, a total of 145 consecutive patients
with he-FH were included in the study. Between
November 2006 and January 2011, we also included 131
consecutive patients with nonanginal chest pain
(NACP) as a control group. Patients with NACP were
used as a substitute for asymptomatic patients with-
out he-FH because the radiation exposure limits the
choice of control subjects to patients with an indica-
tion for cardiac computed tomography (CT) scanning.Patients with NACP were referred by their general
practitioner for the evaluation of chest pain and un-
derwent stress testing and cardiac CT scanning. They
had no history of coronary artery disease (CAD). NACP
was deﬁned as chest pain or discomfort that was not
provoked by exertion or emotional stress or relieved
by rest or nitroglycerin (16).
Patients with he-FHwere recruited fromour tertiary
outpatient lipid clinic. he-FH was determined either
by the presence of a conﬁrmed LDLR or APOB gene
mutation (the patients did not have PCSK9mutations)
or clinically as having untreated LDL-C levels above
the 95th percentile for sex and age in combinationwith
at least 1 of the following: the presence of typical
tendon xanthomas in the patient or a ﬁrst-degree
relative; an LDL-C level above the 95th percentile for
sex and age in a ﬁrst-degree relative; or proven CAD in
a ﬁrst-degree relative aged <60 years (17).
DNA samples were taken of all patients with a
clinical suspicion of he-FH and were sent to a central
laboratory for mutational screening (18). A complete
overview of the mutations found and clinical char-
acteristics of both LDLR-negative and LDLR-defective
he-FH has been published previously (19). Plasma
lipid levels were measured by using the fasting
blood samples at the time of inclusion. Cholesterol
levels before statin treatment were obtained from
patient medical records, and they were used as the
variable untreated maximum total cholesterol and
untreated maximum low-density lipoprotein choles-
terol (maxLDL).
Exclusion criteria were: symptoms of CAD, history
of CAD, rheumatic fever, or known aortic valve pa-
thology (although cardiac ultrasounds were not
routinely performed before study inclusion). Patients
with a secondary cause of hypercholesterolemia (e.g.,
renal, liver, or thyroid disease) were also excluded
from the study. Further exclusion criteria were renal
insufﬁciency (serum creatinine >120 mmol/l), known
contrast allergy, and irregular heart rhythm (atrial
ﬁbrillation). In patients with asymptomatic he-FH,
the inclusion age was 40 to 70 years for men;
women were included if they were older than child-
bearing age because of potential radiation-induced
harm to the fetus or ovaries. Women’s inclusion age
was thus 45 to 70 years.
This study complied with the Declaration of
Helsinki, and the institution’s human research com-
mittee approved the study protocol. All patients
provided written informed consent.
CT CALCIUM SCORE. To quantify the AoVC, as well as
the coronary calcium score, a cardiac CT scan without
contrast medium was performed, which enabled
TABLE 1 Clinical Characteristics
he-FH Group
(n ¼ 145)
Control Group
(n ¼ 131) p Value
General
Age, yrs 52  8 56  9 <0.001
Male 93 (64) 78 (60) 0.432
Body mass index, kg/m2 27  4 27  5 0.309
Smoking (current/former) 41 (28) 45 (35) 0.277
Hypertension* 38 (26) 59 (45) 0.001
Systolic blood pressure, mm Hg 129  7 141  20 <0.001
Diastolic blood pressure, mm Hg 80  10 81  12 0.282
Diabetes mellitus 6 (4) 17 (13) 0.008
Positive family history of premature
coronary artery disease†
102 (70) 65 (50) <0.001
Lipids
Untreated maximum total cholesterol, mmol/l 9.8  2.3 5.5  1.2 <0.001
Untreated maximum LDL-C, mmol/l 7.1  2.2 3.7  1.1 <0.001
Statin use 142 (98) 44 (34) <0.001
Total cholesterol, mmol/l 5.5  1.4 5.3  1.2 0.264
HDL, mmol/l 1.4  0.4 1.4  0.4 0.388
LDL, mmol/l 3.5  1.3 3.5  1.1 0.980
Triglyceride, mmol/l 1.09 (0.80–1.65) 1.32 (0.87–1.79) 0.107
Values are mean  SD, n (%), or median (interquartile range). *Blood pressure >140/90 mm Hg and/or anti-
hypertensive treatment. †Proven coronary artery disease in ﬁrst-degree relative aged <60 years.
Control ¼ patients with nonanginal chest pain; HDL ¼ high density lipoprotein; he-FH ¼ heterozygous familial
hypercholesterolemia; LDL ¼ low-density lipoprotein; LDL-C ¼ low-density lipoprotein cholesterol.
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2689calcium scoring with high accuracy and reproduc-
ibility (20,21). All CT scans were performed on a
dual-source CT scanner (ﬁrst 232 scans: Somatom
Deﬁnition; last 44 scans: Somatom Deﬁnition
FLASH [Siemens Medical Solutions, Forchheim,
Germany]), with application of a prospectively
electrocardiogram-triggered scan protocol with a tube
current of 76 mAs at 70% of the RR-interval. Images
were reconstructed with a slice thickness of 3 mm and
an increment of 1.5 mm by using a medium convolu-
tion kernel (B35f).
Lesions were classiﬁed as AoVC if located within
the aortic valve leaﬂets, exclusive of the aortic
annulus or coronary arteries, and contained $3
contiguous pixels with an attenuation value >130 HU
(2,21). The AoVC score was deﬁned as the quantity of
AoVC expressed in Agatston units, according to the
same lesion deﬁnition as for coronary artery calciﬁ-
cation (CAC), using dedicated software (MMWP,
Siemens Medical Solutions) (22). The CT reading was
performed blinded with regard to patient character-
istics. The absence of AoVC was assigned a score of 0.
Additional information regarding the scan protocol,
including the quantiﬁcation of CAC, has been previ-
ously published (23).
Contrast-enhanced scans were consulted if the
exact location of calciﬁed lesions (in the valve or
aortic root) were unclear.
STATISTICAL ANALYSIS. Categorical variables are
expressed as n (%). Normally distributed continuous
variables are shown as mean  SD and skewed vari-
ables as median (interquartile range). To determine
the differences between he-FH patients and NACP
patients, a Pearson chi-square test was used to
compare binary variables. Continuous variables with
a normal distribution were analyzed with a Student
t test, and skewed variables were assessed by using a
Mann-Whitney U test. Statistical signiﬁcance was
considered at a 2-sided p value <0.05.
We compared the prevalence of AoVC and the
AoVC scores between he-FH and NACP patients in
relationship to age. Age categories were chosen
on the basis of equal patient numbers in all groups
(n ¼ 92 [age range: 40 to 50 years], n ¼ 92 [age
range: 51 to 58 years], and n ¼ 92 [age range: 59 to
70 years]).
To evaluate which variables were associated with
AoVC, a univariable ordinal logistic regression model
was used. Subsequently, the AoVC score (Agatston
units) was divided into 3 groups based on equal dis-
tribution of patients in whom AoVC was present:
1) AoVC score ¼ 0 (n ¼ 190); 2) AoVC score >0 to 37
(n ¼ 43); and 3) AoVC score >37 (n ¼ 43). Variables
associated with AoVC where analyzed in the entirecohort with a multivariable ordinal logistic regression
model to identify a set of predictors of AoVC. An
ordinal regression model was chosen instead of a
linear regression model to investigate the dose–
response relationship between the highly skewed
AoVC variable and other variables. Although correct-
ing the skewness by logistically transformation would
have also been possible, we did not want to change
the data into an artiﬁcial score in the 190 subjects
whose Agatston score was 0.
In addition, the association between the presence
of CAC and AoVC was examined for patients with he-
FH and the control subjects. The differences in dis-
tribution of AoVC in the presence and absence of CAC
were analyzed with a Pearson chi-square test, and
differences between the AoVC score in the presence
and absence of CAC were assessed by using the Mann-
Whitney U test. Finally, the inﬂuence of LDLR-
negative and LDLR-defective mutational he-FH on
AoVC was compared. Data were analyzed by using
SPSS version 22 (IBM SPSS Statistics, IBM Corpora-
tion, Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS OF PATIENTS WITH
hE-FH AND CONTROL SUBJECTS. Age, systolic blood
pressure, and the prevalence of hypertension and
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2690diabetes were higher in the control group than in the
he-FH group (Table 1). Patients with he-FH had higher
untreated maxLDL levels, more frequently used sta-
tins, and more often reported a positive family his-
tory for CAD compared with the control subjects. Sex,
body mass index, and treated cholesterol levels were
similar in both groups.
AoVC IN PATIENTS WITH hE-FH AND CONTROL
SUBJECTS. AoVC was compared between patients
with he-FH and control subjects (Table 2). AoVC was
more prevalent in he-FH patients (41%, n ¼ 59) than
in control subjects (21%, n ¼ 27; p < 0.001), irre-
spective of the age category. Limiting the analysis to
patients with AoVC present, the AoVC score (median
[interquartile range]) was higher in he-FH patients
than in control subjects: 51 (9 to 117) and 21 (3 to 49),
respectively (p ¼ 0.007).
RISK FACTORS FOR AoVC. Risk factors for AoVC are
shown in Table 3. The AoVC burden according to the
Agatston score was associated with age, untreated
maxLDL, LDLR-negative mutational he-FH, CAC, and
diastolic blood pressure. Sex, smoking, hypertension,
diabetes mellitus, and obesity were not associated
with the extent of AoVC.
In the multivariable ordinal regression model, all
variables explained 27% of the variance of AoVC, and
all remained signiﬁcantly associated with AoVC.
Among the variables, LDLR-negative mutation carrier
status was a strong predictor of the extent of AoVC
(odds ratio: 4.81; 95% conﬁdence interval: 2.22 to
10.40; p < 0.001). Analyses restricted to the he-FH,
LDLR-defective, and LDLR-negative groups had
similar results (data not shown).TABLE 2 Calciﬁcation of the Aortic Valve Leaﬂets
he-FH Group
(n ¼ 145)
Control
Group
(n ¼ 131) p Value
AoVC present 59 (41) 27 (21) <0.001
AoVC present, per age category
40 to 50 yrs 16 (26) 0 0.002
51 to 58 yrs 21 (48) 8 (17) 0.001
59 to 70 yrs 22 (56) 19 (36) 0.005
AoVC score* 51 (9–117) 21 (3–49) 0.007
AoVC score per category <0.001
Agatston ¼ 0 86 (59) 104 (79) –
Agatston >0–37 24 (17) 19 (15) –
Agatston >37 35 (24) 8 (6) –
Values are n (%) or median (interquartile range). Age categories were chosen on
the basis of equal patient numbers in all groups (n ¼ 92). Aortic valve calciﬁcation
(AoVC) score categories chosen on the basis of equal distribution of patients with
AoVC (n ¼ 43). *Median AoVC score (Agatston units) of patients with AoVC
present.
Abbreviations as in Table 1.ASSOCIATION BETWEEN CAC AND AoVC. The
presence of CAC was associated with a higher preva-
lence of AoVC, both in he-FH patients and in the
control subjects (Table 4). Of the patients without
CAC, #4% exhibited AoVC. However, in the absence
of AoVC, >39% of patients exhibited CAC.
AoVC AND LDLR MUTATIONAL STATUS. Of 145 pa-
tients with he-FH, 59 (41%) had an LDLR-negative
mutation. Compared with the he-FH patients with
LDLR-defectivemutations, LDLR-negativemutational
he-FH was associated with: higher total cholesterol
(5.8  1.6 mmol/l and 5.3  1.3 mmol/l, respectively;
p¼0.026), LDL-C (3.9 1.4mmol/l and 3.21.1mmol/l;
p ¼ 0.002), and untreated maxLDL (8.0  2.5 mmol/l
and 6.6  1.7 mmol/l; p < 0.001). In addition, he-FH
patients with LDLR-negative mutations were younger
(51  7 years and 53 8 years; p¼ 0.040), started statin
treatment at a younger age (40 9.8 years and 46 9.4
years; p<0.001), and used statins for a longer period of
time (10  7 years and 7  7 years; p ¼ 0.010). None of
the other variables from Table 1 were statistically
different between groups.
he-FH patients with LDLR-negative mutations had
a higher prevalence of AoVC (n ¼ 31 [53%]) compared
with those with LDLR-defective mutations (n ¼ 28
[33%]; p < 0.001) and control subjects (n ¼ 27 [21%];
p ¼ 0.016). The difference in AoVC prevalence
between patients with LDLR-defective mutational
he-FH and the control subjects was also signiﬁcant
(p ¼ 0.048). In addition, AoVC scores increased faster
with age in LDLR-negative he-FH patients than in
those with LDLR-defective he-FH (data not shown).
DISCUSSION
The main ﬁndings of the present study are: 1) the
prevalence and extent of AoVC were higher in
patients with he-FH than in those with nonfamilial
hypercholesterolemia; 2) age, untreated maxLDL,
LDLR-negative mutational he-FH, and diastolic blood
pressure were positively associated with AoVC; 3) the
level of treated LDL-C was not predictive of the
prevalence and extent of AoVC; and 4) the absence of
CAC was associated with a low prevalence of AoVC
(Central Illustration).
A recent study by Smith et al. (24) using Mendelian
randomization found that a genetic predisposition to
elevated LDL-C was associated with the presence of
AoVC and the incidence of functional aortic stenosis
in large community-based cohorts. According to the
authors, their results provide evidence supportive of
a causal association between LDL-C and aortic valve
disease. We also performed a Mendelian randomiza-
tion assessment, which is a combination of: 1) an
TABLE 3 Predictive Value of Risk Factors for AoVC Score (N ¼ 276)
Univariable Ordinal Regression
in the Entire Cohort
Multivariable Ordinal Regression
in the Entire Cohort*
Proportional
Odds† 95% CI p Value
Proportional
Odds† 95% CI p Value
LDLR-negative mutation‡ 3.87 2.19–6.84 <0.001 4.81 2.22–10.40 <0.001
Age, yrs‡ 1.07 1.04–1.11 <0.001 1.12 1.08–1.16 <0.001
Male 1.40 0.83–2.37 0.212
BMI 1.05 0.99–1.11 0.106
Smoking (current/ former) 1.24 0.73–2.11 0.433
Hypertension§ 0.84 0.58–3.32 0.518
Diabetes mellitus 0.72 0.30–1.70 0.452
Untreated maximum total
cholesterol
1.33 1.21–1.46 <0.001
Untreated maximum LDL-C‡ 1.26 1.13–1.39 <0.001 1.18 1.03–1.34 0.01
Treated total cholesterol 1.09 0.90–1.31 0.373
HDL 1.02 0.54–1.95 0.943
LDL 1.10 0.90–1.36 0.349
Triglyceride 0.98 0.81–1.19 0.842
Systolic blood pressure 1.01 0.99–1.03 0.065
Diastolic blood pressure‡ 1.03 1.00–1.05 0.031 1.04 1.01–1.07 0.01
CAC (per 100 Agatston units
increase)
1.26 1.16–1.36 <0.001
CAC (present) 6.97 3.18–15.29 <0.001
Agatston units: group 1 (AoVC score ¼ 0), group 2 (AoVC score >0 to 37), and group 3 (AoVC score >37). *No signiﬁcant interaction between the presence of AoVC and other
risk factors. †Because 3 ranked categories (3 AoVC groups) are being analyzed, the proportional odds variable is a relative risk that is calculated with an ordinal logistic
regression analysis. This model predicts how much an increase in the explanatory variable leads to an increase of probability in the higher AoVC group. ‡Relevant variables (p <
0.05) that were entered in the multivariable regression model. §Blood pressure >140/90 mm Hg and/or antihypertensive treatment.
BMI ¼ body mass index; CAC ¼ coronary artery calciﬁcation (Agatston units); CI ¼ conﬁdence interval; LDLR ¼ low-density lipoprotein receptor; R2 ¼ Nagelkerke R square;
other abbreviations as in Tables 1 and 2.
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2691association of the genetic background (the LDLR
mutation), with the intermediate trait (untreated
maxLDL) and the outcome parameter (AoVC); and 2)
an association between the intermediate trait (un-
treated maxLDL) and the outcome parameter (AoVC),
corrected for confounding by multiple regression
analysis. This Mendelian randomization approach
mimics a randomized controlled trial on a genetic
level and suggests a causal role of LDL-C in beginning
aortic valve pathology.TABLE 4 Association Between the Presence of CAC and AoVC for
Patients With he-FH and Control Subjects
CAC Present CAC Absent p Value
he-FH (n ¼ 145)
AoVC present 56 (39) 3 (2) <0.001
AoVC absent 61 (42) 25 (17)
AoVC score* 55 (13–125) 3 (0–3) 0.019
Control (n ¼ 131)
AoVC present 22 (17) 5 (4) 0.002
AoVC absent 51 (39) 53 (40)
AoVC score* 15 (2–44) 24 (10–98) 0.257
Values are are n (%) or median (interquartile range). *Median AoVC score of pa-
tients with AoVC (in Agatston units).
Abbreviations as given in Tables 1 to 3.In the present study, patients with he-FH were
exposed to extremely high levels of LDL before their
statin treatment, especially those with LDLR-negative
mutational he-FH. This approach could have caused
the higher prevalence and quantity of AoVC that we
found in patients with he-FH, and particularly those
with LDLR-negative mutations. The patients were
treated with statins since they were diagnosed with
hypercholesterolemia, which dramatically lowered
LDL-C levels; this approach thereby also reduced the
predictive value of LDL-C toward AoVC. This could
explain why untreated maxLDL and LDLR-negative
mutational he-FH were predictive of AoVC and why
the level of statin-treated LDL-C was not predictive of
AoVC in our study.
Diastolic blood pressure was mildly but signiﬁ-
cantly associated with AoVC in our overall normo-
tensive subjects. One might speculate that the
increased diastolic blood pressure promotes stress on
the aortic side of the valve leaﬂets, which is where
aortic valve lesions are most commonly found (25).
This increased stress on the aortic valve can lead to
tissue remodeling and promote inﬂammation,
resulting in calciﬁcation, stenosis, and ultimately
valve failure (26).
CENTRAL ILLUSTRATION Severity of AoVC in Patients With he-FH and Control Subjects, and Their Untreated LDL-C Levels
 Subjects in Each Severity
          Group of AoVC
   22
(51%)    13
(30%)
    8
(19%)
6.6 ± 2.5 mmol/L
8.0 ± 2.5 mmol/L
3.7 ± 1.1 mmol/L
LDLR Negative    LDLR-Defective          Control
Mean Untreated MaxLDL
0
2
4
6
8
  104
(55%)
    19
(44%)
    9
(21%)
   15
(35%)
   28
(15%)
   58
(30%)
No Calcification
     AoVC Score: 0
Mild Calcification
   AoVC Score: >0-37
Severe Calcification
       AoVC Score: >37
ten Kate, G.-J.R. et al. J Am Coll Cardiol. 2015; 66(24):2687–95.
In this study, 145 asymptomatic patients with heterozygous familial hypercholesterolemia (he-FH) and 131 nonfamilial hypercholesterolemia control
subjects underwent computed tomography calcium scoring of the aortic valve. Severity of aortic valve calciﬁcation (AoVC) per group is shown in the
pie charts, and the bar graph illustrates the untreated low-density lipoprotein (LDL-C) levels for the groups. LDLR ¼ low-density lipoprotein receptor;
MaxLDL ¼ untreated maximum low-density lipoprotein cholesterol.
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2692Using electron-beam CT scans, Messika-Zeitoun
et al. (27) investigated determinants and progression
of AoVC in a population-based follow-up study. New
AoVC was found to be associated with elevated LDL-C
levels, whereas established AoVC progressed inde-
pendently of atherosclerotic risk factors and faster
with increasing initial extent of AoVC. This led to the
hypothesis that elevated levels of LDL-C produce
their atherogenic effect during the early phase of
AoVC, before the start of statin treatment.As shown in the Results section, patients with
LDLR-negative mutational he-FH started statin
treatment at a younger age and used statins for a
longer period of time. However, despite their more
intense statin treatment, these patients exhibited a
higher prevalence of AoVC, which increased more
rapidly with age. To investigate the effect of statin
treatment on AoVC in our cohort of he-FH patients,
whom we knew were exposed to high levels of LDL-C
early in life, we included “duration of statin use” in a
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2693multivariable ordinal regression model. Duration of
statin use, however, was not associated with AoVC
after correction for age, untreated maxLDL, LDLR-
negative mutational he-FH, and diastolic blood
pressure. All other variables remained statistically
signiﬁcant (data not shown).
In addition, 3 major prospective randomized trials
found no impact of lipid-lowering therapy on the rate
of progression of AoVC (28–30). However, macro-
phage and osteoclast inﬁltration of the AoVC were
reduced by atorvastatin in cholesterol-fed mice (31).
Apparently, other pathogenic risk mechanisms pre-
vail once AoVC has been established. It is known that
during the later stages of calciﬁc aortic stenosis, a
process of osteoblastic activity prevails over the
initial atherosclerotic process, resulting in progres-
sive calciﬁcation of the valve that seems unrelated to
LDL-C levels or statin treatment and ﬁts the observed
independence of AoVC from lipid proﬁle or statin
treatment. The extensive AoVC in our young study
population suggests that statins create their main
effect in preventing aortic valve pathology before the
development of aortic valve stenosis. The 3 prospec-
tive randomized trials were restricted to patients with
beginning aortic valve pathology in whom statins
could no longer exert a preventive effect. Although
the exact role of serum lipids in the pathogenesis of
aortic valve disease is unknown, it is evident that
lipid depositions are found within and in proximity to
aortic valve lesion, which is not the case in healthy
valve leaﬂets (25). This ﬁnding suggests a critical role
for lipids in the early onset of aortic valve pathology.
The concept of 2 different phases in the develop-
ment of AoVC progression is not only essential in
comprehending the effect of statin treatment but
could also explain the discordant association between
AoVC and CAC. As shown in Table 4, the absence of
CAC was associated with a very low prevalence of
AoVC. The absence of AoVC was not predictive of the
absence of CAC, however. It is possible, during the
early phase of AoVC, that risk factors for CAC are
preconditions for the development of AoVC. Howev-
er, if AoVC develops after the initial atherosclerotic
phase, its progression seems to be regulated by risk
factors that differ from those causing CAC (27,32–34).
We found that the prevalence and extent of sub-
clinical AoVC are clearly increased in patients with
he-FH, especially in those carrying LDLR-negative
mutations. It should be emphasized that AoVC is
generally without symptoms, and only a fraction of
patients with AoVC ultimately develop clinical aortic
stenosis. The reported prevalence of hemodynami-
cally signiﬁcant aortic valve stenosis on echocardi-
ography is low in he-FH (15). Since statin therapybecame available, the risk of cardiovascular disease
mortality has been substantially reduced in patients
with he-FH (35).
Detection and treatment of patients with he-FH at
a young age may not only slow progression of CAD
but could also be effective in preventing or slowing
the development of AoVC during the early phase of
disease. This outcome underlines the clinical impor-
tance of studies on the effectiveness of statin use for
the primary prevention of AoVC, especially in pa-
tients with LDLR-negative mutational he-FH.
STUDY LIMITATIONS. This study was a cross-sectional
observation of AoVC in patients aged between
40 and 70 years, without clinical outcome data and
without functional assessment of stenosis with
echocardiography. The cross-sectional design of our
study did not allow for proper evaluation of the ef-
fects of statins on AoVC, which would require a pro-
spective study and sequential imaging. In addition,
we do not have sufﬁcient follow-up in our cohort to
assess the clinical consequences of the observed
AoVC, which is a limitation of the study’s observa-
tional design.
Only asymptomatic patients were selected for
study. It remains to be seen if patients with AoVC will
eventually develop clinical aortic valve disease, given
that the majority of AoVC will not lead to aortic ste-
nosis (36).
The current selection of patients with he-FH who
were referred to our university lipid clinic may have
more severe AoVC compared with he-FH patients in
the general population. This single-center study from
a tertiary hospital could have resulted in over-
estimation of the total prevalence and extent of
AoVC. However, this potential selection bias should
equally hold for LDLR-negative and LDLR-defective
mutations.
We have analyzed patients with a major locus ef-
fect in the cholesterol metabolism, but we cannot
exclude contributions from variants of other genes,
such as NOTCH1 (37,38); calciﬁed bicuspid aortic
valves have an especially high heritability. Bicuspid
aortic valves have an estimated prevalence of 1% to
2%. The linkage peaks of aortic stenosis and the
NOTCH1 gene have not been found on chromosome
19, which is where the LDLR is located (19p13.2).
Without co-segregation with the mutations in the
LDLR, it is unlikely that our cohort was enriched with
variants of these other genes.
Recent studies on coronary atherosclerosis showed
that the calciﬁed plaque component increased after
long-term statin therapy (39,40). In our study, pa-
tients with he-FH and particularly patients with
LDLR-negative mutations received higher dosages of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
high prevalence and large extent of aortic valve
calciﬁcation in treated heterozygous familial hyper-
cholesterolemia (FH) patients suggests that aortic
valve pathology will be a common problem among
the aging statin-treated heterozygous FH patients.
TRANSLATIONAL OUTLOOK: Future research
should be directed toward developing more accurate
cardiovascular risk prediction tools.
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2694statins for longer periods of time, and statin use could
therefore be a more complex confounder in our ana-
lyses. However, in our multivariable ordinal regres-
sion model, the time of statin treatment was not
signiﬁcantly associated with AoVC in patients with
he-FH.
Male sex was not found to be a risk modiﬁer of
AoVC in our study patients compared with the gen-
eral population. This is likely caused by the relatively
small size of our study compared with the large
population-based Heinz Nixdorf RECALL (Risk Fac-
tors, Evaluation of Coronary Calcium and Lifestyle
Factors) study or the Multi-Ethnic Study of Athero-
sclerosis (2,5,27).
CONCLUSIONS
According to the results of the present study, we
concluded that: he-FH was associated with a high
prevalence and a large extent of subclinical AoVC; age,
diastolic blood pressure, untreated maxLDL, and
LDLR-negative mutations were associated with the
extent of AoVC; the difference between LDLR-negative
and LDLR-defective mutations provides important
evidence for the critical role of LDL-C metabolism for
the pathogenesis of AoVC; and the absence of CAC was
associated with a low prevalence of AoVC, suggesting
shared pathophysiological determinants. Worldwide,
the majority of patients with he-FH who have beentreated with statins for a substantial period of their life
are still too young to have developed valve disease.
However, due to the prolonged survival in these pa-
tients because of statin treatment, our results suggest
that aortic valve pathology will be a common problem
in aging patients with he-FH, especially in those with
LDLR-negative mutations.
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